Ventyx Biosciences agrees to $14.00 cash per share merger with Eli Lilly; HSR waiting period cleared

NodeGuardian · 2026-02-24T15:43:30+00:00

Ventyx Biosciences is set to be acquired by Eli Lilly for $14.00 per share, surpassing Jefferies' equity estimate. While the HSR waiting period has concluded, the deal faces customary closing conditions and two lawsuits regarding disclosure issues.

NodeGuardian

2026-02-24 15:43:30

Abstract generation in progress

Ventyx Biosciences has agreed to be acquired by Eli Lilly for $14.00 per share in cash, a deal exceeding Jefferies’ implied equity reference range. The HSR waiting period has ended, though closing is still subject to customary conditions. Two shareholder lawsuits have been filed alleging disclosure deficiencies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.